CERo Therapeutics Announces Activation of the University of California, Davis as a Clinical Trial Site for the Ongoing Phase 1 CERTAIN-T Trial of CER-1236 in Hematologic Malignancies

SOUTH SAN FRANCISCO, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTCQB: CERO) ("CERo" or the "Company"), an innovative cellular immunotherapy company advancing engineered T cell therapeutics designed to engage phagocytic mechanisms, today announced that the University of California, Davis (UC Davis), has been activated as a clinical trial site for CERTAIN-T, the Company's ongoing Phase 1 study evaluating CER-1236 in patients with hematologic malignancies. UC Davis also serves as the primary manufacturing site for CER-1236.